» Articles » PMID: 30176842

Epidemiological Study of Hepatitis B and Hepatitis C Infections in Northeastern China and the Beneficial Effect of the Vaccination Strategy for Hepatitis B: a Cross-sectional Study

Abstract

Background: Viral hepatitis, mainly hepatitis B and C, is a serious public health problem worldwide. In China, the prevalence of hepatitis B virus (HBV) infection remains high, while that of hepatitis C virus (HCV) infection is controversial. This study investigated the epidemiology of HBV and HCV infections and assessed the beneficial effect of the vaccination strategy for hepatitis B in Northeastern China.

Methods: From June 2016 to August 2016, 6541 residents of Changchun in Northeastern China were recruited for this cross-sectional study. Demographic characteristics as well as HBV and HCV serological test results were reviewed and analyzed.

Results: Among all study participants, 3.8% and 0.36% tested positive for hepatitis B surface antigen (HBsAg) and anti-HCV, respectively. The HBsAg- and anti-HCV-positive rates were significantly higher in male participants (4.58% and 0.43%) than in female individuals (3.0% and 0.33%). Notably, among all age groups, the lowest rate of HBsAg positivity (0.2%) was found in children born after the implementation of the vaccination strategy for hepatitis B. Conversely, participants aged 40-49 years had significantly greater positive rates of HBsAg (5.9%) compared with those of other age groups. Furthermore, the highest rates of anti-HCV positivity (1.1%) were observed in participants aged 50-59 years.

Conclusions: The rate of HBsAg-positivity declined significantly following successful implementation of the policy on hepatitis B vaccination, indicating a beneficial impact on the control of HBV infection. However, only a slight decrease was observed in the anti-HCV-positivity rate, identifying an area in need of improvement within viral hepatitis prevention and control programs in China.

Citing Articles

Characteristics of patients with chronic hepatitis B infection in China: A retrospective claims database study.

Meng X, Gillespie I, Dong J, Ning Y, Kendrick S Medicine (Baltimore). 2024; 103(7):e36645.

PMID: 38363906 PMC: 10869091. DOI: 10.1097/MD.0000000000036645.


Screening of hepatitis B and C viral infection, recognition of risk factors, and immunization of patients against hepatitis B virus: a module developed for effective hepatitis control.

Ejaz S, Abdullah I, Malik W, Anjum S, Ashraf M, Akhtar N Front Public Health. 2023; 11:1269209.

PMID: 38106902 PMC: 10721974. DOI: 10.3389/fpubh.2023.1269209.


Complementary Presence of HBV Humoral and T-cell Response Provides Protective Immunity after Neonatal Immunization.

Huang Y, Yang Y, Wu T, Li Z, Xu H, Huang A J Clin Transl Hepatol. 2022; 10(4):660-668.

PMID: 36062290 PMC: 9396322. DOI: 10.14218/JCTH.2021.00272.


Systematic Review of Hepatitis C Virus Prevalence in the WHO Western Pacific Region.

Iversen J, Wand H, Chan P, Le L, Maher L Viruses. 2022; 14(7).

PMID: 35891529 PMC: 9320901. DOI: 10.3390/v14071548.


Evaluation of the effect of enhanced immunization in adults: A cross-sectional study in the southeast city of China.

Ren W, Wu Z, Liu Y, Qiu Y, Yao J, Ren J Hum Vaccin Immunother. 2022; 18(6):2096972.

PMID: 35878394 PMC: 9746406. DOI: 10.1080/21645515.2022.2096972.


References
1.
Vos T, Flaxman A, Naghavi M, Lozano R, Michaud C, Ezzati M . Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2163-96. PMC: 6350784. DOI: 10.1016/S0140-6736(12)61729-2. View

2.
. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018; 3(6):383-403. DOI: 10.1016/S2468-1253(18)30056-6. View

3.
Chen Y, Li L, Cui F, Xing W, Wang L, Jia Z . [A sero-epidemiological study on hepatitis C in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2012; 32(9):888-91. View

4.
Zhang Q, Qi W, Wang X, Zhang Y, Xu Y, Qin S . Epidemiology of Hepatitis B and Hepatitis C Infections and Benefits of Programs for Hepatitis Prevention in Northeastern China: A Cross-Sectional Study. Clin Infect Dis. 2015; 62(3):305-12. DOI: 10.1093/cid/civ859. View

5.
Cui Y, Jia J . Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013; 28 Suppl 1:7-10. DOI: 10.1111/jgh.12220. View